Hereditary Angioedema Clinical Trials
Here are the 6 most popular medical studies for hereditary angioedema
Kallikrein Inhibitor
Ecallantide for Angioedema
The investigators will conduct a double-blind, randomized controlled trial comparing the safety and effectiveness of ecallantide to conventional therapy. A rescue cross-over design will be used such that patients failing to improve on standard therapy will additionally be treated with ecallantide. Therefore, a historical control cohort will be enrolled for analysis of secondary endpoints. In addition, since some patients treated with conventional therapy may improve rapidly and therefore not be eligible for inclusion in the study, the investigators will enroll these patients as an observational arm to enable the conduct of sensitivity analysis.
Growth Hormone Therapy for Pseudohypoparathyroidism
This trial is observing the effects of growth hormone on patients with Albright hereditary osteodystrophy, specifically those with pseudohypoparathyroidism type 1a. This form of the condition typically leads to patients being short and obese. The trial is also observing the neurocognitive and psychosocial effects of the condition in order to better understand how to manage it.
Device Validation Using Blood Samples for Thrombotic Thrombocytopenic Purpura
This trial is for a new device that needs to be validated with known samples. 3 ml of blood is needed from people diagnosed with hTTP. You will be compensated for your time and resources.
Popular filter options for hereditary angioedema trials
HAE Clinical Trials
View 13 HAE medical studies.
Antisense Oligonucleotide
Donidalorsen for Hereditary Angioedema
This trial will test the safety and effectiveness of a drug called Donidalorsen for treating hereditary angioedema (HAE). The drug will be given as a shot under the skin, and different doses and frequencies will be tested.
Phase 3 Hereditary Angioedema Clinical Trials
View 37 phase 3 hereditary angioedema medical studies.
RNAi Therapeutics
Vutrisiran vs Patisiran for Amyloidosis
This trial is studying vutrisiran, which is given as a shot under the skin, to see how well it works compared to patisiran, which is given as a drip into a vein, for people with hereditary ATTR amyloidosis. People will get vutrisiran or patisiran once every 3 months or 3 weeks, respectively, for 18 months. The trial will use the placebo arm of the APOLLO study as an external comparator for the primary and most other efficacy endpoints during the 18 Month Treatment Period. Following the 18 Month Treatment Period, all participants will be randomized to receive
Hereditary Angioedema Clinical Trials With No Placebo
View 37 hereditary angioedema medical studies that do not have a placebo group.
RNAi Therapeutics
Vutrisiran vs Patisiran for Amyloidosis
This trial is studying vutrisiran, which is given as a shot under the skin, to see how well it works compared to patisiran, which is given as a drip into a vein, for people with hereditary ATTR amyloidosis. People will get vutrisiran or patisiran once every 3 months or 3 weeks, respectively, for 18 months. The trial will use the placebo arm of the APOLLO study as an external comparator for the primary and most other efficacy endpoints during the 18 Month Treatment Period. Following the 18 Month Treatment Period, all participants will be randomized to receive
View More Hereditary Angioedema Trials
See another 13 medical studies focused on hereditary angioedema.
Frequently Asked Questions
Introduction to hereditary angioedema
What are the top hospitals conducting hereditary angioedema research?
In the realm of hereditary angioedema research, several hospitals have made significant progress in their clinical trials. AARA Research Center in Dallas leads the way with five ongoing trials and a total of 30 studies dedicated to this condition throughout their history. Since conducting their first hereditary angioedema trial in 2005, they have been at the forefront of understanding and treating this rare genetic disorder. Meanwhile, Washington University School of Medicine in Saint Louis has also emerged as a prominent institution for research on hereditary angioedema. With four active trials and an impressive eleven completed studies thus far, their contributions since starting their inaugural trial in 2010 are noteworthy.
Additionally making valuable contributions is Optimed Research, LTD based in Columbus. This facility currently has three active clinical trials focused on hereditary angioedema and has conducted ten previous investigations since initiating their first trial back in 2009.
Notably joining these leading institutions is Ionis Investigative Site located both in Santa Monica and Dallas; though relatively new to the scene having recorded its initial investigation only last year (2020), it is actively pursuing three concurrent hereditary angioedema trials alongside three past endeavors exploring this field.
These hospitals form a network of expertise that collectively advances our understanding and treatment options for individuals living with hereditary angioedema - an uncommon yet impactful condition characterized by recurrent episodes of swelling beneath the skin's surface. The dedication exhibited by these institutions not only offers hope for affected individuals but reinforces our commitment to unraveling mysteries surrounding genetic disorders while improving lives through innovation within medical science
Which are the best cities for hereditary angioedema clinical trials?
When it comes to hereditary angioedema clinical trials, several cities have emerged as key players in research and development. Dallas, Texas leads the pack with 12 active trials focusing on investigational treatments like Donidalorsen, KVD900 600 mg, and Donidalorsen: Cohort A. Following closely behind are Santa Monica, California and Saint Louis, Missouri with 11 ongoing studies exploring similar interventions. Additionally, Hershey, Pennsylvania and Scottsdale Arizona each offer 10 active trials investigating potential breakthroughs for hereditary angioedema treatment options. These cities provide individuals with access to cutting-edge clinical trials that pave the way for advancements in care for those living with this condition.
Which are the top treatments for hereditary angioedema being explored in clinical trials?
The field of hereditary angioedema (HAE) research is abuzz with exciting developments in clinical trials. Leading the charge is KVD900 600 mg, currently being explored in three active trials for HAE since its listing in 2022. Not far behind is donidalorsen, making waves with two ongoing trials and four all-time HAE studies since its introduction in 2020. Also worth noting is berotralstat, showing promising potential with one active trial and one all-time HAE study after debuting in 2022. These groundbreaking treatments offer hope for individuals affected by HAE and pave the way for improved management strategies moving forward.
What are the most recent clinical trials for hereditary angioedema?
Exciting advancements in clinical trials for hereditary angioedema offer hope and potential treatments for individuals affected by this condition. Among the recent studies, povorcitinib has shown promise as a possible therapy. This Phase 2 trial evaluates the efficacy of povorcitinib at different doses specifically tailored for hereditary angioedema patients. Another study focuses on pazopanib, examining its effectiveness at a dose of 150 mg during both Phase 2 and Phase 3 trials. Additionally, single-dose cohort trials are being conducted to assess various treatment options for hereditary angioedema. These ongoing efforts highlight the commitment to finding effective therapies that can improve the lives of those living with hereditary angioedema
What hereditary angioedema clinical trials were recently completed?
In the realm of hereditary angioedema, several clinical trials have recently concluded, showcasing advancements in potential treatments. Notably, Shire completed a trial for Lanadelumab in both February 2021 and May 2020. Another significant development occurred with CSL Behring's completion of a trial for CSL312 in January 2021. Furthermore, BioCryst Pharmaceuticals conducted two separate trials: one for BCX7353 capsules and another for BCX7353, both concluding in February 2018. These recent endeavors demonstrate the ongoing commitment to finding effective therapies for individuals grappling with hereditary angioedema.